Kaken Pharmaceutical Co., Ltd.
JPX: 4521.T0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Tokyo Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Hiroyuki Horiuchi
- Employees
- 1,135
- Headquarters
- Tokyo, Japan
- IPO year
- 2001
- Market cap
- ¥152.6B
- Website
- https://www.kaken.co.jp
Loading 4521…
Loading profile data…Frequently asked questions about 4521
What does Kaken Pharmaceutical Co., Ltd. (4521.T) do?
Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. It offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Seprafilm, a semitransparent film-type absorbable adhesi...
Where does 4521.T trade?
Kaken Pharmaceutical Co., Ltd. (4521.T) trades on the Tokyo Stock Exchange.
What sector is 4521.T in?
Kaken Pharmaceutical Co., Ltd. (4521.T) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Kaken Pharmaceutical Co., Ltd.?
Hiroyuki Horiuchi is the chief executive officer of Kaken Pharmaceutical Co., Ltd. (4521.T).
Where is Kaken Pharmaceutical Co., Ltd. headquartered?
Kaken Pharmaceutical Co., Ltd. is headquartered in Japan.
Does 4521.T pay a dividend?
Yes — Kaken Pharmaceutical Co., Ltd. (4521.T) paid a trailing twelve-month dividend of JPY 190.00 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 4521.T go public?
Kaken Pharmaceutical Co., Ltd. (4521.T) completed its initial public offering in 2001.